A dose-finding study of cannabidiol in dogs with idiopathic epilepsy

Epilepsy is currently reported to affect approximately 5% of the canine population; of that number approximately 30% of dogs are poorly controlled on routine anti-epileptic drugs (AEDs). Recent CBD research has demonstrated the anti-convulsive properties in both canine and human patients; however, to-date a dose finding study has not been performed in veterinary patients. In the second phase of this study, we’re looking at the dose chosen in the first phase over a period of 6 months to determine if this dose is effective in producing an adequate number of responders (50% or greater reduction in seizure frequency).

Once it has been verified that initial criteria have been met, dogs will come to CSU to have a neurologic examination, undergo an MRI and CSF tap, and have bloodwork performed, including AED levels, to rule out any obvious causes of epilepsy. At this visit we will also check a CBD level to ensure there’s no current CBD in the system. If a dog has already had an MRI and CSF tap performed recently it will not be necessary to repeat. After the MRI and CSF tap, you will go home with a 3-month supply of CBD oil to be given twice daily. You will be required to come to CSU at month 3 and month 6 so we can check bloodwork and perform an exam.

Out-of-state enrollments may be accepted on a case-by-case basis.

condition(s)

epilepsy

eligibility information

  • At least 2 generalized seizures every 6 weeks for the past 6 months
  • On at least one conventional anti-epileptic medication for at least 6 months at an appropriate dose
  • At least 1 year old
  • Normal neurological exam
  • Systemically healthy with no evidence of life-limiting disease processes
  • Willing and able to commit to no medication changes for the 6 month duration of the trial

Enrollment Deadline

Enrollment ends May 15, 2024

contact information

If interested in enrolling, please email the neurology clinical trials team at csuneurotrials@colostate.edu with your dog’s name, age, seizure history, and current medications. You’re also encouraged to include primary care veterinarians and any veterinary neurologists your pet has seen.

CSU ram head with green background
Neurology Clinical Trials
Study Coordinator: Breonna Kusick, Primary Investigator: Stephanie McGrath